AcelRx Pharmaceuticals, Inc. (ACRX) — Recommendation Trends

Dsuvia is for the management of acute pain in trauma and ambulatory settings

Dsuvia is for the management of acute pain in trauma and ambulatory settings

The Stock now has a Weekly Volatility of 10.39% and Monthly Volatility of 8.90%. Royal Bank Of Canada's price objective points to a potential upside of 132.56% from the company's current price.

The company showed 4.79 diluted EPS growth for trailing twelve months. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 3rd. The firm has "Buy" rating by H.C. Wainwright given on Tuesday, May 3. The firm has "Hold" rating given on Tuesday, August 1 by Cowen & Co.

Some buy side analysts are also providing their Analysis on AcelRx Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 3 analysts have given a Buy signal, 2 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. TH Capital has "Buy" rating and $15 target. In current trading day Immune Pharmaceuticals, Inc.

Shares of the company plummeted as much as 62.6 percent to $2.00 on Thursday. The company has market cap of $96.43 million.

AcelRx Pharmaceuticals, Inc. has its outstanding Shares of 46.95 Million. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -3.6%. However the company reported $-0.25 earnings per share for the same quarter during a year ago. Seaport Global upgraded AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) on Friday, May 6 to "Buy" rating. AcelRx Pharmaceuticals, Inc. (ACRX) maintained activity of 2.22 million shares that trade hands on average basis while its relative volume is 13.10. Virtu KCG Holdings LLC increased its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. (NASDAQ:ACRX)'s stock about -63.48% from the 50-day high and 5.00% away from the 50-day low. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of US and worldwide copyright law. Goldman Sachs Group stated it has 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). (NASDAQ:ACRX)'s stock was -17.31%. The shares were bought at an average price of $2.95 per share, for a total transaction of $29,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the business's stock in a transaction dated Monday, October 2nd. About 5.08 million shares traded or 74.57% up from the average.

Apple might ditch Touch ID altogether for next year's iPhones
The iPhone 7 is relatively new, but the iPhone 6s is already two years old. iPhone X also brings new animated emojis to iPhones. This means the FaceID will stay a major selling point for the company for the next year at least, if not more.

Simeone in Awe of Barcelona`s Messi
Since joining the Catalan giants from Premier League club Liverpool in 2010, Mascherano has been impressive for the Spanish club. Argentina coach Jorge Sampaoli revealed that he referred to Messi to help inspire his players before the match.

Pranab was most qualified to be PM: Manmohan Singh
Mukherjee said in the book he has described the coalition years and tried not to bring in any personal matters. Singh also said that he became a politician by accident, while Mukherjee "is a politician by choice".

Meeder Asset Inc owns 1,673 shares. The disclosure for this sale can be found here.

They hope that the stock price will fall or that the company will fail and go bankrupt, leading the equity holders to ruin. AcelRx Pharmaceuticals had 18 analyst reports since August 4, 2015 according to SRatingsIntel. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company's stock worth $355,000 after acquiring an additional 6,942 shares in the last quarter. WealthTrust Axiom LLC increased its position in shares of AcelRx Pharmaceuticals by 50.0% during the 2nd quarter.

Several institutional investors and hedge funds have recently modified their holdings of the company.

"We remain focused on the NDA resubmission and our mission to provide physicians and patients with precise and efficient non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings", said CEO Vincent J. Angotti. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Latest News